0001171843-20-008353.txt : 20201204 0001171843-20-008353.hdr.sgml : 20201204 20201203205910 ACCESSION NUMBER: 0001171843-20-008353 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201203 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201204 DATE AS OF CHANGE: 20201203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 201368405 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_120320.htm FORM 8-K Form 8-K
0000882796 False 0000882796 2020-12-03 2020-12-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 3, 2020

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware 000-23186 62-1413174
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock BCRX Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 7.01. Regulation FD Disclosure.

On December 3, 2020, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved oral, once-daily ORLADEYO™ (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years and older. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The Company has established a wholesale acquisition cost (WAC) for ORLADEYO in the United States of $485,004 on an annual basis ($37,308 per 28-day pack of either 150mg or 110mg capsules).

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including statements regarding the Company's plans and expectations for ORLADEYO. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from any future results, performances, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of the Company's business, including without limitation delays, stoppages, difficulties and increased expenses with respect to the Company's and its partners' development, regulatory processes, and supply chains, negatively impact the Company's ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents the Company files periodically with the Securities and Exchange Commission (SEC); the Company's ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; the outcome of pricing, coverage, and reimbursement negotiations with third-party payors for ORLADEYO; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA, EMA, PMDA, or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, including to support the continued commercialization of ORLADEYO, may not provide regulatory clearances, which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, including ORLADYEO, may impose a clinical hold with respect to such product candidates, or may withhold or withdraw market approval for such product candidates; the Company's ability to successfully manage its growth and compete effectively; risks related to the international expansion of the Company's business; and actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents the Company files periodically with the SEC, specifically the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results and developments to differ materially from those contained in the Company's forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit No.   Description
     
99.1   Press release dated December 3, 2020 entitled "BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients"
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  BioCryst Pharmaceuticals, Inc.
     
   
Date: December 3, 2020 By:  /s/ Alane Barnes        
    Alane Barnes
    Senior Vice President and Chief Legal Officer
   

 

 EX-99.1 2 exh_991.htm EXHIBIT 99.1 EdgarFiling

EXHIBIT 99.1

BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

—Significant and sustained reduction in HAE attacks—

—Oral, once-daily prophylactic option enables HAE patients to reduce burden of therapy1 —

—ORLADEYO approved for adult and pediatric patients 12 years and older—

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved oral, once-daily ORLADEYO™ (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

“ORLADEYO offers people with HAE and their physicians the first orally administered non-steroidal option for preventing HAE attacks and represents an important and welcome step in making more treatment options available to physicians and patients,” said Anthony J. Castaldo, president and chief executive officer of the US Hereditary Angioedema Association (HAEA). 

In the pivotal Phase 3 APeX-2 trial, ORLADEYO significantly reduced attacks at 24 weeks, and this reduction was sustained through 48 weeks. HAE patients who completed 48 weeks of treatment (150 mg) saw reductions in their HAE attack rates, from a mean of 2.9 attacks per month at baseline to a mean of 1.0 attacks per month after 48 weeks of therapy. In the long-term open label APeX-S trial, patients completing 48 weeks of therapy (150 mg) had a mean attack rate of 0.8 attacks per month.

ORLADEYO was safe and well tolerated in both trials. The most frequently reported adverse reactions in patients receiving ORLADEYO compared with placebo were gastrointestinal reactions. These reactions generally occurred early after initiation of treatment with ORLADEYO, became less frequent with time and typically self-resolved.

“Patients and physicians acknowledge that HAE treatments can add a burden to patients’ lives.  As an oral, once-daily option, ORLADEYO can provide significant attack reduction and lessen the burden associated with injections and infusions,” said Marc Riedl, M.D., professor of medicine and clinical director, U.S. Hereditary Angioedema Association Center at the University of California, San Diego, and an investigator in the APeX-2 trial.

“With this new treatment option, physicians and patients can continue to have collaborative discussions to choose the treatment that meets each patient’s needs, life circumstances and preferences,” Riedl added.

HAE patients note a significant treatment burden associated with existing prophylactic therapy. In addition to reducing HAE attack rate, data from APeX-2 show that patients reported meaningful improvements in both quality of life and overall patient-reported satisfaction, and significant reductions in their monthly use of standard of care on-demand medicine, while taking oral, once-daily ORLADEYO (150 mg).2,3

“The FDA approval of ORLADEYO fulfills a promise BioCryst made to HAE patients that we were committed to helping them achieve the dream of an oral, once-daily medicine to prevent and reduce the burden of their attacks,” said Jon Stonehouse, president and chief executive officer of BioCryst.

“Thank you to the HAE patients who participated in our clinical trials, to the investigators around the world who conducted these trials, to the HAEA for their patient advocacy and to our employees who never forgot that patients were waiting. We will stay focused on enabling access and providing personalized support to HAE patients and physicians,” Stonehouse added.

Commitment to Patient Access

BioCryst is committed to supporting HAE patients taking ORLADEYO through a new program designed to streamline access to therapy. Through EMPOWER Patient Services, each HAE patient and their healthcare provider will have a single point of contact for access to ORLADEYO. A dedicated care coordinator will support access for each patient with comprehensive financial support tools and reimbursement support.

EMPOWER Patients Services is administered by Optime Care Inc., the exclusive specialty pharmacy provider for ORLADEYO. Physicians can begin writing prescriptions for ORLADEYO immediately, with direct to patient shipments from Optime Care expected to begin by the end of December 2020.

Additional information is available at www.ORLADEYO.com and 1-866-5-EMPOWER (1-866-536-7693).

About ORLADEYO™ (berotralstat)
ORLADEYO™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.  One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

U.S. Indication and Important Safety Information

INDICATION
ORLADEYO™ (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION
An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company’s website at www.biocryst.com.

Forward-Looking Statements 

This press release contains forward-looking statements, including statements regarding BioCryst’s plans and expectations for ORLADEYO.  These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, including to support the continued commercialization of ORLADEYO, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, including ORLADEYO, may impose a clinical hold with respect to such product candidates, or may withhold or withdraw market approval for such product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management's expected ranges.  Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW

Contacts:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com


________________________
1 Radojicic, C, et al. Patient Perspectives on the Treatment Burden of Injectable Medication Administration for Hereditary Angioedema. Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; Poster 160, Nov (2020)

2 Johnston, D.T., et al. Berotralstat Improves Patient-Reported Quality of Life Through 48 Weeks in the Phase 3 APeX-2 Trial; Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; Poster 154, Nov (2020) 

3 Jacobs, J, et al. Berotralstat Positively Impacts Patient-Reported Satisfaction: Results from the Phase 3 APeX-2 trial; Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; Poster 158, Nov (2020)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf57a925-5da4-4c72-8a93-02e9c4308123

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_120320_htm.xml IDEA: XBRL DOCUMENT 0000882796 2020-12-03 2020-12-03 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2020-12-03 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Dec. 03, 2020
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 03, 2020
Entity File Number 000-23186
Entity Registrant Name BioCryst Pharmaceuticals, Inc.
Entity Central Index Key 0000882796
Entity Tax Identification Number 62-1413174
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4505 Emperor Blvd., Suite 200
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27703
City Area Code 919
Local Phone Number 859-1302
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_120320.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_120320.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_120320.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_120320.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_120320.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-20-008353-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-008353-xbrl.zip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�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

TH !G;G'-D4$L! A0#% @ 9*>#4>U2I(%8" ^F4 !0 M ( !URL &=N=RTR,#$Y,#$P,5]D968N>&UL4$L! A0#% @ 9*>#45G+ M&IL*"P L8L !0 ( !830 &=N=RTR,#$Y,#$P,5]L86(N M>&UL4$L! A0#% @ 9*>#4<^(&H:6!P FV !0 ( ! MG3\ &=N=RTR,#$Y,#$P,5]P&UL4$L%!@ & 8 >0$ &5' ! $! end